Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib in Progressive Multiple Sclerosis Without Relapse
NCT05441488Phase 3Suspended
- Sponsor
- AB Science
- Start
- Jun 2022
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Masitinib (4.5) with Placebo (2 arms). Primary endpoint: Time to confirmed progression at 96 weeks. Started Jun 2022; status: suspended.
02
Drugs
masitinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05441488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05441488.